We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

XL Dermal Graft Matrix Supports Reconstructive Surgery

By HospiMedica International staff writers
Posted on 10 Nov 2021
Print article
Image: The new AlloMend extra-large ADM (Photo courtesy of AlloSource)
Image: The new AlloMend extra-large ADM (Photo courtesy of AlloSource)
A new acellular dermal matrix (ADM) with a large footprint aids demanding soft tissue applications in plastic and reconstructive surgery.

The AlloSource (Centennial, CO, USA) AlloMend Extra-Large (XL) ADM comes in meshed and non-meshed varieties, with a footprint of 16cm x 20cm (320 cm2) for use in demanding soft tissue applications, with both options featuring a one cm non-meshed border for secure and easy suturing. The increased surface area also enables increased fluid egress, helping protect the area from seroma formation. Additionally, the meshing allows graft expansion to provide greater adaptability in reconstruction procedures.

AlloMend ADM is processed using proprietary DermaTrue decellularization process, which removes cellular debris (including DNA, RNA, proteins, and antigens), rendering the tissue acellular and with low immunologic response, while still retaining growth factors and a collagen structure. In addition, terminal sterilization with e-beam technology to a sterility assurance level (SAL) of 10-6, minimizes infection risk, while avoiding damaging the allograft tissue. AlloMend ADM is also shelf-stable and comes pre-hydrated, so it is immediately ready-to-use.

“Based on AlloSource's twenty seven years of manufacturing skin grafts, we have seen surgeons switch to new reconstruction techniques, which requires larger dermal grafts for single piece coverage,” said Ross Wilkins, MD, senior medical director of AlloSource. “AlloMend XL was created with the purpose to help surgeons provide better options for outcomes for their patients.”

Enhancing fluid egress reduces the risk of seroma, which can slow vascular ingrowth and postpone integration of a tissue graft. Further, increasing the surface area of an ADM graft that comes in contact with the patient’s vascularized native tissue may allow for more rapid vascularization and faster patient recovery.

Related Links:
AlloSource


Print article
Radcal
NUVO

Channels

Business

view channel
Image: 44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience (Photo courtesy of IHF)

44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience

The 44th World Hospital Congress (WHC) organized by The International Hospital Federation (IHF; Geneva, Switzerland) on 8-11 November 2021 in Barcelona, Spain came to an upbeat close. During the event,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.